0001829126-22-014634.txt : 20220726 0001829126-22-014634.hdr.sgml : 20220726 20220726083358 ACCESSION NUMBER: 0001829126-22-014634 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20220721 ITEM INFORMATION: Unregistered Sales of Equity Securities ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20220726 DATE AS OF CHANGE: 20220726 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Organicell Regenerative Medicine, Inc. CENTRAL INDEX KEY: 0001557376 STANDARD INDUSTRIAL CLASSIFICATION: MISCELLANEOUS TRANSPORTATION EQUIPMENT [3790] IRS NUMBER: 474180540 STATE OF INCORPORATION: NV FISCAL YEAR END: 1031 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-55008 FILM NUMBER: 221104971 BUSINESS ADDRESS: STREET 1: 4045 SHERIDAN AVENUE STREET 2: SUITE 239 CITY: MIAMI STATE: FL ZIP: 33140 BUSINESS PHONE: 888-963-7881 MAIL ADDRESS: STREET 1: 4045 SHERIDAN AVENUE STREET 2: SUITE 239 CITY: MIAMI STATE: FL ZIP: 33140 FORMER COMPANY: FORMER CONFORMED NAME: Biotech Products Services & Research, Inc. DATE OF NAME CHANGE: 20150917 FORMER COMPANY: FORMER CONFORMED NAME: BESPOKE TRICYCLES INC DATE OF NAME CHANGE: 20120831 8-K 1 organicellregenrative_8k.htm 8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934

Date of report (Date of earliest event reported): July 21, 2022

ORGANICELL REGENERATIVE MEDICINE, INC.

(Exact name of registrant as specified in its charter)

Nevada	000-55008	47-4180540
(State or Other Jurisdiction	(Commission File Number)	(IRS Employer
of Incorporation)		Identification No.)

4045 Sheridan Avenue, Suite 239, Miami Beach, Florida		33140
(Address of Principal Executive Offices)		(Zip Code)

Registrant’s telephone number, including area code: (888) 963-7881

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each Class		Trading Symbol		Name of each exchange on which registered
None		N/A		N/A

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

As used in this Current Report on Form 8-K, and unless otherwise indicated, the terms “the Company,” “Organicell,” “we,” “us” and “our” refer to Organicell Regenerative Medicine, Inc. and its subsidiaries.

Item 3.02 Unregistered Sales of Equity Securities

The information set forth under Item 5.02 is incorporated herein by reference.

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

(a) Effective July 21, 2022 (the “Effective Date”), Albert Mitrani stepped down as the Company’s Chief Executive Officer and was appointed by the Board of Directors to the position of Executive Vice President of Sales.

(b) On the Effective Date, Matthew Sinnreich was appointed by the Board of Directors to the position of Chief Operating Officer and Acting Chief Executive Officer.

For more than the last five years, Mr. Sinnreich, 36, has been a self-employed entrepreneur, investor and developer in the real estate, securities and development stage company fields. Either individually, or as a partner in various entities, he has purchased and sold various properties, including luxury homes and developed, managed and operated a number of real estate projects, including an apartment building and various office and commercial properties. In connection therewith, Mr. Sinnreich has also been responsible for securing the financing for these projects. He has also met success in securities trading for his own account, in the equity, derivative and debt fields. Mr. Sinnreich has also been adept at providing equity and debt financing, both directly as an investor and with various business partners and corporate advisory services for various early-stage companies, including Organicell. Mr. Sinnreich holds a bachelor’s degree from the University of Miami School of Business.

On the Effective Date, Organicell and Mr. Sinnreich entered into a term sheet (the “Term Sheet”) setting forth in principle the terms of Mr. Sinnreich’s employment agreement with and compensation by the Company. Except with respect to the signing bonus described below, the Term Sheet is subject to the negotiation and execution of a definitive employment agreement embodying the provisions of the Term Sheet, as well as customary terms and conditions for an executive employment agreement (the “Employment Agreement”). The parties agreed to use their respective commercial best efforts to negotiate and execute the Employment Agreement within thirty (30) days of the Effective Date.

The Term Sheet provides that as an inducement for Mr. Sinnreich to join the Company, within five (5) days of the Effective Date, he will be issued 10,000,000 shares of restricted common stock and ten-year warrants to purchase 40,000,000 shares at a price of $0.034 per share, exercisable on a “cashless” basis. The foregoing shares and warrants vest immediately upon issuance.

The Employment Agreement will provide for an initial two-year term commencing on the Effective Date (the “Initial Term”), which will automatically renew for successive one-year terms (each a “Renewal Term,” and together with the Initial Term, the “Term”), unless terminated by either party upon not less than ninety (90) days’ prior written notice given before the expiration of the Initial Term or a Renewal Term, or earlier terminated as provided for therein.

1

During the first year of the Initial Term, Mr. Sinnreich will be compensated by the issuance of 24,000,000 shares of Organicell’s common stock, which shall vest in equal monthly installments of 2,000,000 shares each. During the second year of the Initial Term, Mr. Sinnreich will be entitled to receive a base salary of $25,000 per month, payable in cash of shares of Organicell’s common stock, at his election.

The Employment Agreement will provide that Mr. Sinnreich will be entitled to receive a bonus payment of $150,000, if and when during the Term, the Company generates $10,000,000 in funding from an equity line of credit arrangement that may be implemented by the Company in the future. In addition, Mr. Sinnreich will be entitled to receive an award of 15,000,000 shares of common stock if any of the following milestones are achieved during the Term and the twelve month period thereafter (provided the Employment Agreement and Mr. Sinnreich’s employment thereunder is terminated by the Company without cause).

1.

The Company first obtains market capitalization of $1.0 billion for a three month consecutive period.

2.

The Company first obtains market capitalization of $2.0 billion for a three month consecutive period.

3.

The Company first obtains market capitalization of $5.0 billion for a three month consecutive period.

4.

The Company first obtains market capitalization of $10.0 billion for a three month consecutive period.

The offer and sale of the above referenced securities were and will be issued in private transactions exempt from the registration requirements of the Securities Act of 1933, as amended (the “Securities Act”), in reliance on exemptions afforded by Section 4(a)(2) of the Securities Act and the rules and regulations promulgated thereunder.

(c) On July 26, 2022, the Company issued a press release disclosing the above-referenced changes in management. A copy of the press release is filed as Exhibit 99.1 hereto.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits. The following exhibits are filed with this report:

Exhibit No.		Description
99.1		Press Release dated July 26, 2022

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: July 26, 2022	ORGANICELL REGENERATIVE MEDICINE, INC.

	By:	/s/ Ian Bothwell
		Ian Bothwell Chief Financial Officer

3

EX-99.1 2 organicellregenrative_ex99-1.htm EXHIBIT 99.1

Exhibit 99.1

ORGANICELL ANNOUNCES MATT SINNREICH AS CEO

Miami, FL (July 26, 2022) — Organicell Regenerative Medicine, Inc. (OTCQB: OCEL), a clinical-stage biopharmaceutical company principally focusing on the development of innovative biological therapeutics in the extracellular vesicle space, announced today that the board of directors has appointed Matt Sinnreich as Chief Operating Officer and acting CEO. Sinnreich will replace Mr. Albert Mitrani, the founder of Organicell and CEO since September 2019, who is stepping down to serve as the Company’s EVP of sales.

Sinnreich, an early-stage investor in Organicell, helped fund the company’s audit in 2020 to bring their financials current and was instrumental in the creation of their flagship brand: Zofin.

Sinnreich comes from a development and entrepreneurial background. His track record includes profitable corporate exits, successful real estate transactions, and owner-operated residential and commercial real estate developments. Sinnreich has closed tens of millions in various financing instruments including everything from traditional real estate debt, fundraising for private companies, to collateralized derivatives and swaps.

Sinnreich is an early-stage investor in the ready to drink tequila-seltzer, Mamitas and owns a minority interest in Craig’s Vegan Ice Cream.

Sinnreich graduated from the University of Miami Business School in 2008 where he also won the 2008 Rothschild Business Plan Competition.

In response to his appointment, Sinnreich stated:

“I am humbled and grateful that the board and new investment groups have entrusted me to take Organicell to the next level. I believe that exosomes are a key element in the future of medicine and this company has the team to make that a reality. Albert and Mari Mitrani are pioneers in this space. They have assembled an incredible science team, developed an amazing product line, and built top tier production labs. All the ingredients are here for this company to become a major success.

As COO and acting CEO I will be focused on creating additional financing vehicles, growing the awareness of our products and brand, and most importantly maintaining an honest, transparent relationship with the shareholders.

My priorities right now are to work with our CFO, Ian Bothwell, to build out Organicell’s core executive team. I will pull from my network to surround myself with the best and brightest in the medical and financial arenas. I plan to create a robust ERP and data management system and to set up additional financing vehicles to fund our clinical trials.

I will also be taking to market Organicell’s newest biological product: Patient Pure X™ (PPX™).

PPX™ is Organicell’s first autologous product that is a non-manipulated biologic that concentrates a patient’s exosomes from their own peripheral blood. In plain English: we can concentrate a patient’s exosomes from their own blood.

Organicell’s science team and researchers are currently conducting studies to prove PPX’s effectiveness on pain, hair loss, its potential for aesthetic uses, and surgical recovery.

Organicell’s products have shown promising results in the early-stage data that has been collected. Once the company has the adequate data from our clinical trials to make the claims we are studying – I believe this company will be a disrupter in the biotech industry.”

About Organicell Regenerative Medicines, Inc.

Organicell Regenerative Medicine, Inc. (OTCQB:OCEL) is a clinical-stage biopharmaceutical company principally focusing on the development of innovative biological therapeutics for the treatment of degenerative diseases and the provision of other related services. The Company’s proprietary products are derived from perinatal sources and manufactured to retain the naturally occurring exosomes, hyaluronic acid, and proteins without the addition or combination of any other substance or diluent. To learn more, please visit https://organicell.com/.

Forward-Looking Statements

Certain of the statements contained in this press release should be considered forward-looking statements within the meaning of the Securities Act of 1933, as amended (the “Securities Act”), the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and the Private Securities Litigation Reform Act of 1995. These forward-looking statements are often identified by the use of forward-looking terminology such as “will”, “believes”, “expects”, “potential”, or similar expressions, involving known and unknown risks and uncertainties. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, they do involve assumptions, risks and uncertainties, and these expectations may prove to be incorrect. We remind you that actual results could vary dramatically as a result of known and unknown risks and uncertainties, including but not limited to: potential issues related to our financial condition, competition, the ability to retain key personnel, product safety, efficacy and acceptance, the commercial success of any new products or technologies, success of clinical programs, ability to retain key customers, our inability to expand sales and distribution channels, legislation or regulations affecting our operations including product pricing, reimbursement or access, the ability to protect our patents and other intellectual property both domestically and internationally, and other known and unknown risks and uncertainties, including the risk factors discussed in the Company’s periodic reports that are filed with the SEC and available on the SEC’s website (http://www.sec.gov). You are cautioned not to place undue reliance on these forward-looking statements. All forward-looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by these risk factors. Specific information included in this press release may change over time and may or may not be accurate after the date of the release. Organicell has no intention and specifically disclaims any duty to update the information in this press release.

Media Contact:

Joshua Rodriguez

CEO and Founder

CNA Finance, LLC.

(503) 464-6502

EX-101.LAB 3 bpsr-20220721_lab.xml XBRL LABEL FILE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 4 bpsr-20220721_pre.xml XBRL PRESENTATION FILE EX-101.SCH 5 bpsr-20220721.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink XML 6 R1.htm IDEA: XBRL DOCUMENT

Cover	Jul. 21, 2022
Cover [Abstract]
Document Type	8-K
Amendment Flag	false
Document Period End Date	Jul. 21, 2022
Entity File Number	000-55008
Entity Registrant Name	ORGANICELL REGENERATIVE MEDICINE, INC.
Entity Central Index Key	0001557376
Entity Tax Identification Number	47-4180540
Entity Incorporation, State or Country Code	NV
Entity Address, Address Line One	4045 Sheridan Avenue
Entity Address, Address Line Two	Suite 239
Entity Address, City or Town	Miami Beach
Entity Address, State or Province	FL
Entity Address, Postal Zip Code	33140
City Area Code	(888)
Local Phone Number	963-7881
Written Communications	false
Soliciting Material	false
Pre-commencement Tender Offer	false
Pre-commencement Issuer Tender Offer	false
Entity Emerging Growth Company	false

XML 7 organicellregenrative_8k_htm.xml IDEA: XBRL DOCUMENT 0001557376 2022-07-21 2022-07-21 iso4217:USD shares iso4217:USD shares 0001557376 false 8-K 2022-07-21 ORGANICELL REGENERATIVE MEDICINE, INC. NV 000-55008 47-4180540 4045 Sheridan Avenue Suite 239 Miami Beach FL 33140 (888) 963-7881 false false false false false EXCEL 8 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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

M-8?20$3;8T.P6BP^0"X99K>]9!:G%C:^?VZH:TE[VE-S9NMQ=%A?BTX'HE'QY%V)N:I%F MGJ:QJ,';>$<-!)U4Q-Z*0CZFL6&P9:P!Q+MTFF6SU%L,9KD8M;:X1+_)UW,#ECQ ,ZE._<]'<')O$8T.,5RMQD)HDU75Z(\4I!K-L53,[E M9C(,]L""Q1]ZUYG\M(?8,V(/'U:-Y&:6J6"%'*7?Z/6M>CR#+@^H%7I")\!K M*_#,U#88CIV,IDAO8O0]C.=0XIS_4R-5%1:PIJ+U$&3HD<%U!D.LL8DF"=9# M;E9T!N[RZ .;O\P M>=0>6N=6RKV'5[+E&''\GN4/4$L#!!0 ( #Q$^E0D'INBK0 /@! : M >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'.UD3T.@S ,A:\2Y0 U4*E# M!4Q=6"LN$ 7S(Q(2Q:X*MR^% 9 Z=&&RGBU_[\E.GV@4=VZ@MO,D1FL&RF3+ M[.\ I%NTBB[.XS!/:A>LXEF&!KS2O6H0DBBZ0=@S9)[NF:*'3^ 5!+ P04 " \1/I499!YDAD! #/ M P $P %M#;VYT96YT7U1Y<&5S72YX;6RMDTU.PS 0A:\295LE+BQ8H*8; M8 M=< %C3QJK_I-G6M+;,T[:2J 2%85-K'C>O,^>EZS>CQ&PZ)WUV)0=47P4 M E4'3F(=(GBNM"$Y2?R:MB)*M9-;$/?+Y8-0P1-XJBA[E.O5,[1R;ZEXZ7D; M3?!-FI6.5Z*U .EK >MKBRAE#VQH%.JB]XY8:8P*IL0,@9^O1=#%- M)IXPC,^[V?S!9@K(RDT*$3FQ!'_'G2/)W55D(TADIJ]X(;+U[/M!3EN#OI'- MX_T,:3?D@6)8YL_X>\87_QO.\1'"[K\_L;S63AI_YHOA/UY_ 5!+ 0(4 Q0 M ( #Q$^E0'04UB@0 +$ 0 " 0 !D;V-0&UL4$L! A0#% @ /$3Z5(]F673N *P( !$ M ( !KP &1O8U!R;W!S+V-O&UL4$L! A0#% @ /$3Z5)E< MG",0!@ G"< !, ( !S $ 'AL+W1H96UE+W1H96UE,2YX M;6Q02P$"% ,4 " \1/I4T4:_?!$$ !D#P & @($- M" >&PO=V]R:W-H965T&UL4$L! A0#% @ /$3Z5)^@ M&_"Q @ X@P T ( !5 P 'AL+W-T>6QE&PO=V]R:V)O;VLN>&UL4$L! A0#% @ /$3Z5"0>FZ*M M ^ $ !H ( !>1$ 'AL+U]R96QS+W=O9(9 0 SP, !, M ( !7A( %M#;VYT96YT7U1Y<&5S72YX;6Q02P4& D "0 ^ @ J!, # end XML 9 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 10 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 11 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.2 html 1 20 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://organicell.com/role/Cover Cover Cover 1 false false All Reports Book All Reports organicellregenrative_8k.htm bpsr-20220721.xsd bpsr-20220721_lab.xml bpsr-20220721_pre.xml organicellregenrative_ex99-1.htm http://xbrl.sec.gov/dei/2022 true false JSON 13 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "organicellregenrative_8k.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "organicellregenrative_8k.htm" ] }, "labelLink": { "local": [ "bpsr-20220721_lab.xml" ] }, "presentationLink": { "local": [ "bpsr-20220721_pre.xml" ] }, "schema": { "local": [ "bpsr-20220721.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd", "https://xbrl.sec.gov/country/2022/country-2022.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd" ] } }, "elementCount": 59, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2022": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 20, "memberCustom": 0, "memberStandard": 0, "nsprefix": "bpsr", "nsuri": "http://organicell.com/20220721", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "organicellregenrative_8k.htm", "contextRef": "From2022-07-21to2022-07-21", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "role": "http://organicell.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "organicellregenrative_8k.htm", "contextRef": "From2022-07-21to2022-07-21", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://organicell.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://organicell.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://organicell.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://organicell.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://organicell.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://organicell.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://organicell.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://organicell.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r11", "r13", "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://organicell.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://organicell.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://organicell.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://organicell.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://organicell.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://organicell.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://organicell.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://organicell.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://organicell.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://organicell.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://organicell.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://organicell.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://organicell.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://organicell.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://organicell.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://organicell.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://organicell.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://organicell.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://organicell.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://organicell.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://organicell.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://organicell.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://organicell.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://organicell.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r19" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://organicell.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://organicell.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://organicell.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://organicell.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://organicell.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://organicell.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://organicell.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://organicell.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://organicell.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://organicell.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://organicell.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://organicell.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://organicell.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://organicell.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://organicell.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://organicell.com/role/Cover" ], "xbrltype": "trueItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://organicell.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://organicell.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://organicell.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://organicell.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://organicell.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://organicell.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r9" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://organicell.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://organicell.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://organicell.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://organicell.com/role/Cover" ], "xbrltype": "booleanItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r10": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r11": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310" }, "r12": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r13": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f" }, "r14": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f" }, "r15": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r16": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r17": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405" }, "r18": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r19": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d" }, "r7": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r8": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r9": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d" } }, "version": "2.1" } ZIP 14 0001829126-22-014634-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001829126-22-014634-xbrl.zip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